NeoGenomics, Inc. (NEO): Price and Financial Metrics


NeoGenomics, Inc. (NEO): $8.23

0.37 (+4.71%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NEO POWR Grades


  • NEO scores best on the Sentiment dimension, with a Sentiment rank ahead of 59.85% of US stocks.
  • The strongest trend for NEO is in Quality, which has been heading down over the past 179 days.
  • NEO ranks lowest in Value; there it ranks in the 6th percentile.

NEO Stock Summary

  • With a year-over-year growth in debt of 179.6%, Neogenomics Inc's debt growth rate surpasses 93.91% of about US stocks.
  • The volatility of Neogenomics Inc's share price is greater than that of 87.34% US stocks with at least 200 days of trading history.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for NEO comes in at -48.71% -- higher than that of only 9.05% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Neogenomics Inc are CXDO, EVER, KIDS, SHYF, and INGN.
  • Visit NEO's SEC page to see the company's official filings. To visit the company's web site, go to www.neogenomics.com.

NEO Valuation Summary

  • NEO's EV/EBIT ratio is 90; this is 207.17% higher than that of the median Healthcare stock.
  • NEO's price/earnings ratio has moved up 97.9 over the prior 213 months.
  • Over the past 213 months, NEO's EV/EBIT ratio has gone up 106.

Below are key valuation metrics over time for NEO.

Stock Date P/S P/B P/E EV/EBIT
NEO 2021-08-31 12.2 5.2 83.2 90.0
NEO 2021-08-30 12.4 5.3 84.2 91.0
NEO 2021-08-27 12.2 5.2 83.0 89.7
NEO 2021-08-26 11.8 5.0 80.7 87.3
NEO 2021-08-25 11.5 4.9 78.6 85.1
NEO 2021-08-24 11.5 4.9 78.2 84.7

NEO Growth Metrics

    The 5 year cash and equivalents growth rate now stands at 347.93%.
  • Its 3 year net income to common stockholders growth rate is now at 180.41%.
  • Its 5 year revenue growth rate is now at 207.21%.
NEO's revenue has moved up $59,010,000 over the prior 15 months.

The table below shows NEO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 484.329 -26.723 -8.347
2021-09-30 484.594 -0.962 48.828
2021-06-30 488.698 7.331 71.733
2021-03-31 453.951 10.603 -10.964
2020-12-31 444.448 1.46 4.172
2020-09-30 425.319 -1.166 -4.949

NEO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NEO has a Quality Grade of C, ranking ahead of 30.23% of graded US stocks.
  • NEO's asset turnover comes in at 0.366 -- ranking 397th of 561 Business Services stocks.
  • MSFT, VRNS, and SGRP are the stocks whose asset turnover ratios are most correlated with NEO.

The table below shows NEO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.366 0.422 0.085
2021-03-31 0.414 0.399 -0.033
2020-12-31 0.490 0.418 -0.014
2020-09-30 0.508 0.419 -0.033
2020-06-30 0.522 0.433 -0.042
2020-03-31 0.589 0.468 0.016

NEO Price Target

For more insight on analysts targets of NEO, see our NEO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $56.80 Average Broker Recommendation 1.25 (Strong Buy)

NEO Stock Price Chart Interactive Chart >

Price chart for NEO

NEO Price/Volume Stats

Current price $8.23 52-week high $54.74
Prev. close $7.86 52-week low $7.26
Day low $7.76 Volume 1,012,786
Day high $8.29 Avg. volume 1,922,987
50-day MA $11.63 Dividend yield N/A
200-day MA $29.39 Market Cap 1.03B

NeoGenomics, Inc. (NEO) Company Bio


NeoGenomics, Inc. operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company was founded in 2001 and is based in Fort Myers, Florida.


NEO Latest News Stream


Event/Time News Detail
Loading, please wait...

NEO Latest Social Stream


Loading social stream, please wait...

View Full NEO Social Stream

Latest NEO News From Around the Web

Below are the latest news stories about Neogenomics Inc that investors may wish to consider to help them evaluate NEO as an investment opportunity.

NeoGenomics Non-GAAP EPS of -$0.14 beats by $0.01, revenue of $125.73M in-line

NeoGenomics press release (NASDAQ:NEO): Q4 Non-GAAP EPS of -$0.14 beats by $0.01. Revenue of $125.73M (-0.2% Y/Y) in-line. Shares +0.27% PM. Consolidated gross profit for the fourth quarter of 2021 was $45.3 million, a decrease of 21.2%, compared to the fourth quarter of 2020. Adjusted EBITDA was negative $10 million compared...

Seeking Alpha | February 23, 2022

NeoGenomics (NEO) CEO, Mark Mallon on Q4 2021 Results - Earnings Call Transcript

NeoGenomics Inc. (NEO) Q4 2021 Earnings Conference Call February 23, 2022 8:30 am ET Company Participants Mark Mallon - Chief Executive Officer William Bonello - Chief Financial Officer Clive Morris - President, Inivata George Cardoza - President, Chief Operating Officer Gina Waller - President, Pharma Services Clynt Taylor - President,...

SA Transcripts on Seeking Alpha | February 23, 2022

NeoGenomics (NEO) Reports Q4 Loss, Tops Revenue Estimates

NeoGenomics (NEO) delivered earnings and revenue surprises of -7.69% and 0.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 23, 2022

NeoGenomics Reports Full Year Revenue of $484 Million and $126 Million for the Fourth Quarter of 2021

MYERS, FL / ACCESSWIRE / February 23, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced fourth quarter and full year 2021 results for the period ended December 31, 2021.

Yahoo | February 23, 2022

NeoGenomics appoints Dr. Shashi Kulkarni, a World-Renowned Oncology Genomics Expert, and Innovator as Chief Scientific Officer

MYERS, FL / ACCESSWIRE / February 14, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, has announced that Shashikant Kulkarni, M.

Yahoo | February 14, 2022

Read More 'NEO' Stories Here

NEO Price Returns

1-mo -24.15%
3-mo -60.34%
6-mo -77.54%
1-year -79.50%
3-year -61.27%
5-year 11.52%
YTD -75.88%
2021 -36.63%
2020 84.07%
2019 131.96%
2018 42.33%
2017 3.38%

Continue Researching NEO

Here are a few links from around the web to help you further your research on Neogenomics Inc's stock as an investment opportunity:

Neogenomics Inc (NEO) Stock Price | Nasdaq
Neogenomics Inc (NEO) Stock Quote, History and News - Yahoo Finance
Neogenomics Inc (NEO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5929 seconds.